S&P 500   3,821.35
DOW   31,802.44
QQQ   299.94
S&P 500   3,821.35
DOW   31,802.44
QQQ   299.94
S&P 500   3,821.35
DOW   31,802.44
QQQ   299.94
S&P 500   3,821.35
DOW   31,802.44
QQQ   299.94
Log in

SCYNEXIS Stock Forecast, Price & News

+0.13 (+1.60 %)
(As of 03/8/2021 12:00 AM ET)
Today's Range
Now: $8.26
50-Day Range
MA: $8.33
52-Week Range
Now: $8.26
Volume224,750 shs
Average Volume800,754 shs
Market Capitalization$90.36 million
P/E RatioN/A
Dividend YieldN/A
SCYNEXIS, Inc., a biotechnology company, delivers therapies for the treatment fungal infections in the United States. It is developing its lead product candidate, ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company develops ibrexafungerp, which has completed Phase 2 clinical trials for the treatment of vulvovaginal candidiasis. It has research collaborations with Merck Sharp & Dohme Corp. and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was founded in 1999 and is headquartered in Jersey City, New Jersey.


Form 8-K SCYNEXIS INC For: Feb 19 - StreetInsider.com
February 23, 2021 |  streetinsider.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:SCYX
Year FoundedN/A



Sales & Book Value

Annual Sales$120,000.00
Book Value$1.32 per share


Net Income$-53,710,000.00


Market Cap$90.36 million
Next Earnings Date3/10/2021 (Estimated)


Overall MarketRank

1.63 out of 5 stars

Medical Sector

325th out of 1,971 stocks

Pharmaceutical Preparations Industry

154th out of 772 stocks

Analyst Opinion: 4.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
+0.13 (+1.60 %)
(As of 03/8/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SCYX News and Ratings via Email

Sign-up to receive the latest news and ratings for SCYX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

SCYNEXIS (NASDAQ:SCYX) Frequently Asked Questions

Is SCYNEXIS a buy right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for SCYNEXIS in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SCYNEXIS stock.
View analyst ratings for SCYNEXIS
or view top-rated stocks.

What stocks does MarketBeat like better than SCYNEXIS?

Wall Street analysts have given SCYNEXIS a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but SCYNEXIS wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting SCYNEXIS?

SCYNEXIS saw a increase in short interest in the month of January. As of January 29th, there was short interest totaling 650,500 shares, an increase of 97.2% from the January 14th total of 329,800 shares. Based on an average daily trading volume, of 518,400 shares, the days-to-cover ratio is currently 1.3 days. Currently, 6.2% of the company's shares are short sold.
View SCYNEXIS's Short Interest

When is SCYNEXIS's next earnings date?

SCYNEXIS is scheduled to release its next quarterly earnings announcement on Wednesday, March 10th 2021.
View our earnings forecast for SCYNEXIS

How were SCYNEXIS's earnings last quarter?

SCYNEXIS, Inc. (NASDAQ:SCYX) posted its earnings results on Friday, November, 6th. The company reported ($0.28) earnings per share for the quarter, beating the Zacks' consensus estimate of ($1.00) by $0.72.
View SCYNEXIS's earnings history

How has SCYNEXIS's stock price been impacted by Coronavirus?

SCYNEXIS's stock was trading at $7.8020 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, SCYX stock has increased by 5.9% and is now trading at $8.26.
View which stocks have been most impacted by COVID-19

When did SCYNEXIS's stock split? How did SCYNEXIS's stock split work?

Shares of SCYNEXIS reverse split before market open on Friday, July 17th 2020. The 1-10 reverse split was announced on Thursday, July 16th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, July 16th 2020. An investor that had 100 shares of SCYNEXIS stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for SCYX?

7 equities research analysts have issued twelve-month target prices for SCYNEXIS's shares. Their forecasts range from $20.00 to $50.00. On average, they anticipate SCYNEXIS's share price to reach $31.00 in the next year. This suggests a possible upside of 275.3% from the stock's current price.
View analysts' price targets for SCYNEXIS
or view top-rated stocks among Wall Street analysts.

Who are SCYNEXIS's key executives?

SCYNEXIS's management team includes the following people:
  • Dr. Marco Taglietti, CEO, Pres & Director (Age 61, Pay $937.35k)
  • Mr. Eric Francois, Chief Financial Officer (Age 46, Pay $604.91k)
  • Mr. David Gonzalez Angulo, Chief Medical Officer (Age 56, Pay $676.13k)
  • Mr. Scott Sukenick J.D., Gen. Counsel & Corp. Sec. (Age 43)
  • Mr. Jim Maffezzoli, VP of Marketing & Sales

Who are some of SCYNEXIS's key competitors?

What other stocks do shareholders of SCYNEXIS own?

What is SCYNEXIS's stock symbol?

SCYNEXIS trades on the NASDAQ under the ticker symbol "SCYX."

Who are SCYNEXIS's major shareholders?

SCYNEXIS's stock is owned by many different retail and institutional investors. Top institutional investors include Federated Hermes Inc. (19.47%), Caxton Corp (13.48%), Avidity Partners Management LP (11.47%), Stonepine Capital Management LLC (6.26%), Renaissance Technologies LLC (1.18%) and Virtu Financial LLC (0.24%). Company insiders that own SCYNEXIS stock include Brian Philippe Tinmouth, Eric Francois, Marco Taglietti, Perceptive Advisors Llc and Scott Sukenick.
View institutional ownership trends for SCYNEXIS

Which major investors are selling SCYNEXIS stock?

SCYX stock was sold by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP.
View insider buying and selling activity for SCYNEXIS
or view top insider-selling stocks.

Which major investors are buying SCYNEXIS stock?

SCYX stock was acquired by a variety of institutional investors in the last quarter, including Avidity Partners Management LP, Stonepine Capital Management LLC, Caxton Corp, Federated Hermes Inc., Renaissance Technologies LLC, Virtu Financial LLC, Diametric Capital LP, and Jane Street Group LLC. Company insiders that have bought SCYNEXIS stock in the last two years include Brian Philippe Tinmouth, Eric Francois, Marco Taglietti, and Scott Sukenick.
View insider buying and selling activity for SCYNEXIS
or or view top insider-buying stocks.

How do I buy shares of SCYNEXIS?

Shares of SCYX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is SCYNEXIS's stock price today?

One share of SCYX stock can currently be purchased for approximately $8.26.

How much money does SCYNEXIS make?

SCYNEXIS has a market capitalization of $90.36 million and generates $120,000.00 in revenue each year. The company earns $-53,710,000.00 in net income (profit) each year or ($8.10) on an earnings per share basis.

How many employees does SCYNEXIS have?

SCYNEXIS employs 27 workers across the globe.

What is SCYNEXIS's official website?

The official website for SCYNEXIS is www.scynexis.com.

Where are SCYNEXIS's headquarters?


How can I contact SCYNEXIS?

SCYNEXIS's mailing address is 1 EVERTRUST PLAZA 13TH FLOOR, JERSEY CITY NJ, 07302. The company can be reached via phone at 201-884-5485 or via email at [email protected]

This page was last updated on 3/9/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.